论文部分内容阅读
目的探讨维生素D受体(VDR)在乳腺肿瘤中的分布及其与乳腺癌临床病理因素的关系。方法采用免疫组织化学SP法对51例乳腺癌组织及20例乳腺良性肿瘤组织进行ER,PR,HER2和VDR检测,分析VDR与乳腺癌患者年龄、绝经状况、肿瘤大小、有无腋窝淋巴结转移、临床分期、病理类型及组织学分级的关系。对VDR与ER,PR及HER2 3种受体在乳腺癌中的表达率以及表达强度之间的关系进行等级相关性分析。结果VDR在乳腺癌中的表达高于乳腺良性肿瘤(χ2=4.23,P<0.05),乳腺癌中VDR的表达强度与PR,HER2的表达强度呈正相关(rsPR=0.295,P<0.05;rsHER2=0.296,P<0.05)。结论VDR可能影响乳腺癌的发生;维生素D治疗可能提高PR阳性患者内分泌治疗的效果,改善HER2阳性患者的预后。
Objective To investigate the distribution of vitamin D receptor (VDR) in breast cancer and its relationship with clinicopathological factors. Methods Immunohistochemical SP method was used to detect ER, PR, HER2 and VDR in 51 cases of breast cancer and 20 cases of benign breast tumor. The relationship between VDR and age, menopausal status, tumor size, axillary lymph node metastasis, Clinical stage, pathological type and histological grade relationship. The relationship between the expression of VDR and ER, PR and HER2 receptors in breast cancer was analyzed by rank correlation analysis. Results The expression of VDR in breast cancer was higher than that in benign breast tumors (χ2 = 4.23, P <0.05). The expression of VDR in breast cancer was positively correlated with the expression of PR and HER2 (rsPR = 0.295, P <0.05) 0.296, P <0.05). Conclusions VDR may affect the occurrence of breast cancer. Vitamin D treatment may improve the effect of endocrine therapy in PR positive patients and improve the prognosis of patients with HER2 positive.